Data / Drug companies / Aphena Pharma Solutions - Tennessee, LLC
Aphena Pharma Solutions - Tennessee, LLC: 39 products in the FDA NDC directory, labeler code 53401
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Aphena Pharma Solutions - Tennessee, LLC (labeler code 53401) lists 39 products in the FDA National Drug Code Directory, covering 26 finished drugs by generic name. By type: 39 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 24, 2026.
The request: Watch Aphena Pharma Solutions - Tennessee, LLC (FDA labeler code 53401): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 53401
- Products in commercial distribution
- 39
- Packages
- 100
- Finished drugs by generic name
- 26
- Prescription products
- 39
- Over the counter products
- 0
- Controlled substance products
- Schedule V 1
- Started marketing in the last 12 months
- 11
- Products with a marketing end date set
- 1
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 39 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 39 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Metoprolol tartrate | 5 | 46 |
| Metoprolol succinate | 3 | 46 |
| Simvastatin | 3 | 32 |
| Valsartan | 2 | 38 |
| Trazodone hydrochloride | 2 | 39 |
| Propranolol hydrochloride | 2 | 51 |
| Naltrexone hydrochloride | 2 | 24 |
| Allopurinol | 2 | 54 |
| Pregabalin | 1 | 54 |
| Carbidopa and levodopa | 1 | 41 |
| Metoclopramide | 1 | 30 |
| Hydrochlorothiazide | 1 | 51 |
| Methocarbamol | 1 | 67 |
| Escitalopram | 1 | 34 |
| Spironolactone | 1 | 45 |
| Ergocalciferol capsules, | 1 | 9 |
| Famotidine | 1 | 138 |
| Carvedilol | 1 | 35 |
| Sildenafil citrate | 1 | 24 |
| Terazosin | 1 | 11 |
| Valacyclovir | 1 | 27 |
| Dexlansoprazole | 1 | 12 |
| Ticagrelor | 1 | 32 |
| Fluoxetine hydrochloride | 1 | 44 |
| Varenicline | 1 | 11 |
| Hydroxychloroquine sulfate | 1 | 33 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 19 | 48.7% |
| Tablet, film coated | 9 | 23.1% |
| Capsule | 4 | 10.3% |
| Tablet, film coated, extended release | 3 | 7.7% |
| Capsule, extended release | 2 | 5.1% |
| Tablet, coated | 1 | 2.6% |
| Capsule, delayed release | 1 | 2.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sildenafil citrate | 53401-046 | Tablet | Generic drugs (ANDA) | February 24, 2026 |
| Metoprolol tartrate | 53401-017 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Metoprolol tartrate | 53401-016 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Metoprolol tartrate | 53401-015 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Carbidopa and levodopa | 53401-020 | Tablet | Generic drugs (ANDA) | January 19, 2026 |
| Metoprolol succinate | 53401-014 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Metoprolol succinate | 53401-010 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Metoprolol succinate | 53401-009 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Allopurinol | 53401-025 | Tablet | Generic drugs (ANDA) | January 8, 2026 |
| Allopurinol | 53401-019 | Tablet | Generic drugs (ANDA) | January 8, 2026 |
| Pregabalin | 53401-007 | Capsule | Generic drugs (ANDA) | December 10, 2025 |
| Naltrexone Hydrochloride | 53401-023 | Tablet, film coated | Generic drugs (ANDA) | August 15, 2025 |
| Hydroxychloroquine sulfate | 53401-040 | Tablet | Generic drugs (ANDA) | May 8, 2025 |
| Ticagrelor | 53401-028 | Tablet | Generic drugs (ANDA) | April 24, 2025 |
| Trazodone Hydrochloride | 53401-044 | Tablet | Generic drugs (ANDA) | August 8, 2024 |
| Trazodone Hydrochloride | 53401-043 | Tablet | Generic drugs (ANDA) | August 8, 2024 |
| Metoprolol tartrate | 53401-012 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Metoprolol tartrate | 53401-011 | Tablet | Generic drugs (ANDA) | July 26, 2024 |
| Varenicline | 53401-032 | Tablet, film coated | Generic drugs (ANDA) | January 30, 2023 |
| Dexlansoprazole delayed release | 53401-030 | Capsule, delayed release | Generic drugs (ANDA) | September 16, 2022 |
| Carvedilol | 53401-045 | Tablet, film coated | Generic drugs (ANDA) | July 29, 2021 |
| Terazosin | 53401-022 | Capsule | Generic drugs (ANDA) | April 30, 2021 |
| Spironolactone | 53401-041 | Tablet, coated | Generic drugs (ANDA) | January 4, 2021 |
| Valsartan | 53401-033 | Tablet | Generic drugs (ANDA) | June 23, 2020 |
| Valsartan | 53401-029 | Tablet | Generic drugs (ANDA) | June 23, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.